2021
Clinical characteristics and outcomes of COVID-19 in haematopoietic stem-cell transplantation recipients: an observational cohort study
Sharma A, Bhatt NS, St Martin A, Abid MB, Bloomquist J, Chemaly RF, Dandoy C, Gauthier J, Gowda L, Perales MA, Seropian S, Shaw BE, Tuschl EE, Zeidan AM, Riches ML, Shah GL. Clinical characteristics and outcomes of COVID-19 in haematopoietic stem-cell transplantation recipients: an observational cohort study. The Lancet Haematology 2021, 8: e185-e193. PMID: 33482113, PMCID: PMC7816949, DOI: 10.1016/s2352-3026(20)30429-4.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsAllogeneic HSCT recipientsAutologous HSCT recipientsHaematopoietic stem cell transplantation recipientsStem cell transplantation recipientsCOVID-19 diagnosisHSCT recipientsNational Cancer InstituteHigh riskAllogeneic HSCTOverall survivalTransplantation recipientsCOVID-19Cancer InstituteCox proportional hazards modelAggressive treatment measuresSurvival 30 daysObservational cohort studyMarrow Transplant ResearchPoor overall survivalAge 50 yearsOverall survival probabilityPlasma cell disordersMonths of transplantationProportional hazards modelNational Institute
2008
Outcomes in Subcutaneous Panniculitis-Like T-Cell Lymphoma (STCL)
Alpdogan O, Ornstein D, Subtil T, Seropian S, Cooper D, Foss F. Outcomes in Subcutaneous Panniculitis-Like T-Cell Lymphoma (STCL). Blood 2008, 112: 3750. DOI: 10.1182/blood.v112.11.3750.3750.Peer-Reviewed Original ResearchSubcutaneous panniculitis-like T-cell lymphomaPanniculitis-like T-cell lymphomaTCR gene rearrangementsT-cell lymphomaRetrospective studyDenileukin diftitoxPoor prognosisT cellsCytotoxic T-cell markersAllogeneic hematopoietic stem cellsT cell receptor expressionCytotoxic chemotherapy regimensMatched-related donorsEvidence of diseaseRare clinical entityAggressive clinical courseT-cell markersMalignant T cellsCell receptor expressionClonal TCR gene rearrangementNovel T cellAllogeneic HSCTMedian followAggressive therapyChemotherapy regimensShould All Patients with Acute Myelogenous Leukemia (AML) Other Than Good Risk Cytogenetics Receive Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) in First Remission?
Alpdogan O, Lenox R, Barile A, Foss F, Shlomchik W, Reuben C, Cooper D, Seropian S. Should All Patients with Acute Myelogenous Leukemia (AML) Other Than Good Risk Cytogenetics Receive Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) in First Remission? Blood 2008, 112: 4396. DOI: 10.1182/blood.v112.11.4396.4396.Peer-Reviewed Original ResearchAllogeneic HSCTUnrelated donorsTransplant related mortalityEffective curative therapyPoor prognostic featuresConditioning protocolFirst remissionElderly patientsSecondary AMLStandard therapySupportive careCurative therapyMedian ageRelated donorsPrognostic featuresAdvanced ageDonor selectionRelated mortalityRI groupMyeloproliferative diseasePatientsIntensity protocolAMLHSCTTherapy